Effective Treatment for Low Bone Density:
The World Health Organization defines osteopenia, or low bone mass that often precedes osteoporosis, as a bone mineral density value between 1 and 2.5 standard deviations below the mean bone mineral density of young adult women (-2.5 < bone mineral density T-score < -1) . The American Association of Clinical Endocrinologists (AACE) now recommends that women with T-scores Calcitonin is a hormone that is produced by the thyroid gland. By reducing blood calcium, it opposes the effects of parathyroid hormone (PTH), produced by the parathyroid glands, which acts to increase calcium in the blood. Increased blood calcium usually indicates decreased calcium in the bones, which can lead to decreased bone density and osteopenia, and eventually osteoporosis. In fact, hyperparathyroidism, or over-activity of the parathyroid glands, can lead to osteoporosis.
To treat the excess amounts of calcium in the blood and restore the balance that leads to stronger bones, calcitonin supplementation – via injection or nasal spray – can be used. Calcitonin is offered in a bioidentical form (Miacalcin (R)) and it acts by decreasing calcium absorption by the intestine, decreasing osteoclast (cells that break down bone) activity, and decrease calcium reabsorption by kidney tubules. Studies have shown that calcitonin is a well-tolerated and effective approach for preventing and treating osteoporosis. 
Eric R. Braverman, M.D.
Dr. Braverman is a Summa Cum Laude and Phi Beta Kappa graduate of Brandeis University and NYU Medical School, did brain research at Harvard Medical School, and trained at an affiliate of Yale Medical School. He is acknowledged worldwide as an expert in brain-based diagnosis and treatment, and he lectures to and trains doctors in anti-aging medicine.